Abstract
Metastasis is the ultimate consequence of cancer progression and the cause of patients’ death across different cancer types. Patients with initial diagnosis of distant disease have a worst 5-year survival compared to patients with localized disease. Therapies that target primary tumors fail to eradicate distant dissemination of cancer. Recently, immunotherapies have improved the survival of patients with metastatic disease, such as melanoma and lung cancer. However, only a fraction of patients responds to immunotherapy modalities that target the host immune system. The need to identify new druggable targets that inhibit or prevent metastasis is, therefore, much needed. Tetraspanins have emerged as key players in regulating cell migration, invasion, and metastasis. By serving as molecular adaptors that cluster adhesion receptors, signaling molecules, and cell surface receptors; tetraspanins are involved in all steps of the metastatic cascade. They regulate cell proliferation, participate in EMT transition, modulate integrin-mediated cell adhesion, and participate in angiogenesis and invasion processes. Tetraspanins have also been shown to modulate metastasis indirectly through exosomes and by regulating cellular interactions in the immune system. Importantly, targeting individual tetraspanin with antibodies has impacted tumor progression. This review will focus on the contribution of tetraspanins to the metastatic process and their potential as therapeutic tumor targets.
Highlights
Malignant transformation of healthy tissues gives rise to cancer, this disease affects millions of people worldwide
Tspan8 and 12, CD9, CD37, CD63, CD81, CD82, and CD151 play a role in cancer progression [5, 6]
It is of note that expression of CD151 in the host contributes to cancer progression—CD151 knockout (KO) mice have fewer skin, melanoma, lung, and prostate cancers than their wild type (WT) counterparts [17,18,19,20]
Summary
Malignant transformation of healthy tissues gives rise to cancer, this disease affects millions of people worldwide. Patients diagnosed with localized disease have a better 5-year survival than patients with distant disease at the time of diagnosis [1]. Monoclonal antibodies (mAbs) are the preferred immunotherapeutic tools to either target the host immune system or to target the tumor [2]. The most common tumor targets are cell surface molecules, such as EGFR, HER2, Mesothelin, CD19, or CD20 whose cell membrane localization, and sometimes tumor-specific expression, or overexpression in comparison to healthy tissues, makes them suitable for antibody-based therapy [2]. More recent approaches to immunotherapy of cancer do not target antigens expressed on tumor cells—they unleash the host immune checkpoint blockade, and have improved the survival of patients with metastatic cancers [3]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have